YOLFTbeta
FutureChem Co.Ltd

FutureChem Co.Ltd

220100 · KQ · Healthcare / Drug Manufacturers - Specialty & Generic

6,250.00KRW-20.00 (-0.32%)

Price History

Full chart

Market Stats

Previous Close6,270.00
Open6,280.00
Day Range6,250.00 – 6,620.00
52-Week Range5,341.66 – 28,254.61
Volume109.68K
Market Cap199.24B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.64
50-Day Avg6,715.93
200-Day Avg12,847.73

About

FutureChem Co.,Ltd engages in the research and development, production, and sale of chemicals, pharmaceuticals, and medical devices in South Korea and internationally. The company offers radioactive pharmaceuticals, including [18F]FDG for the treatment of general cancer diagnosis, PDvue for Parkinson's disease, Alzavue for Alzheimer's disease, and FLT for the lung cancer diagnosis. Its products in pipeline include [18F]FC303, [177Lu]FC705, and 225Ac for the treatment of prostate cancer; F-FMT for brain tumor diagnosis; FC-505 for the treatment of arteriosclerosis and myocardial infarction; FC-211 for Alzheimer's disease; FC-2 for the treatment of hypoxia; FC-3 for solid cancer; FC801 for bladder cancer; and FC901 for the treatment of pulmonary fibrosis. The company also provides automatic synthesis equipment, such as sCUBE-RXN (synthetic), sCUBE-P&F (tablet-formulation), and sCUBE-M (radioactive, metal). In addition, it offers molecular imaging device airway sleeve and disposable cartridges, as well as engages in medical device wholesale and healthcare business. FutureChem Co.,Ltd was founded in 1999 and is headquartered in Seoul, South Korea.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Dae-Yoon Chi
  • Employees72
  • HeadquartersPyeongHwa Building, Seoul, South Korea, 04794, Korea
  • Websitehttps://www.futurechem.co.kr

Leadership

  • Mr. Dae-Yoon ChiChairman of The Board and Chief Executive Officer · b. 1955
  • Heeseop GilExecutive Director

Financials

Income Statement

Currency: KRW2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue1.45B1.63B3.00B5.64B8.17B11.01B11.82B12.57B13.97B17.29B18.67B
Growth (%)-+12.34%+84.48%+87.95%+44.91%+34.86%+7.31%+6.39%+11.09%+23.81%+7.96%
Cost of Revenue1.75B2.96B3.48B7.15B7.65B8.17B9.32B10.86B12.40B14.27B14.37B
Gross Profit-303.73M-1.33B-482.59M-1.51B512.57M2.84B2.50B1.71B1.57B3.02B4.30B
Gross Margin-20.99%-82.10%-16.10%-26.86%6.28%25.79%21.13%13.60%11.23%17.49%23.06%
Operating Expense2.13B2.55B4.05B10.59B6.01B7.73B10.40B14.64B9.98B12.49B12.05B
Operating Income-2.43B-3.88B-4.53B-12.10B-5.50B-4.89B-7.90B-12.93B-8.41B-9.47B-7.75B
Operating Margin-168.08%-238.98%-151.02%-214.79%-67.34%-44.42%-66.85%-102.87%-60.22%-54.75%-41.51%
EBITDA--------8.04B-566.28M-2.61B-4.87B
EBITDA Margin--------63.96%-4.05%-15.09%-26.11%
Net Income-24.53B-27.29B-4.49B-11.97B-5.37B-23.10B-3.42B-13.96B-6.71B-9.42B-11.25B
Net Income Margin-1695.48%-1678.83%-149.77%-212.38%-65.73%-209.76%-28.93%-111.02%-48.03%-54.46%-60.26%
R&D-384.72M628.80M648.95M877.49M1.94B4.17B7.64B2.36B4.18B3.58B
R&D as % of Total Revenue-23.67%20.97%11.52%10.74%17.59%35.32%60.80%16.88%24.16%19.20%
Interest Expense000003.74B1.32B1.36B478.14M649.73M1.04B
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%34.00%11.19%10.79%3.42%3.76%5.58%

Balance Sheet

Currency: KRW2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets-33.11B36.00B64.05B63.21B82.46B77.14B88.72B72.83B74.42B74.53B
Total Liabilities-1.58B8.80B47.59B52.05B39.08B24.42B18.58B8.92B20.04B19.70B
Total Equity-31.53B27.20B16.46B11.16B43.37B52.72B70.14B63.77B54.38B54.65B
Cash-17.45B6.07B6.25B-110-140.03M3.56B3.19B8.61B5.97B4.34B
Total Debt----14.90B15.63B-----
Net Debt----30.58B16.00B11.18B5.89B---

Cash Flow

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow--1.48B-2.20B-2.84B-3.34B-2.71B-2.28B-2.95B-7.61B-3.72B-3.21B-2.43B
Investing Cash Flow--1.68B-6.56B-12.74B-34.91B68.46M-21.15B4.30B-15.91B19.66B-11.49B-
Financing Cash Flow-5.53B20.67B4.20B38.44B-1.05B24.71B-1.66B23.20B-10.52B11.91B-
Capital Expenditure01.14B796.46M6.05B8.34B6.93B3.44B8.39B2.99B2.42B1.88B8.53B
Free Cash Flow-------5.78B-12.93B-11.57B-8.44B-5.09B-10.95B
FCF to OCF------253.98%438.70%152.01%226.89%158.65%451.33%

Earnings

Report DateMay 15, 2017Aug 11, 2017Nov 13, 2017Feb 19, 2018May 14, 2018Aug 20, 2018Nov 13, 2018Feb 25, 2019May 15, 2019Aug 13, 2019Nov 12, 2019Feb 6, 2020May 13, 2020Aug 14, 2020Nov 13, 2020Jan 28, 2021Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate--------------------------------------
EPS Actual-88.85-83.49-99.41-154.82-137.02-215.68-201.87-781.02-137.55-40.16-272.51-48.65-334.77-283.39-242.88-910.83127.25-115.09-85.11-70.65-121.60-92.48-172.07-189.79-35.28-85.48-61.81-62.17-68.32-126.04-128.95-20.25-89.3494.57-139.51-275.47-74.9882.88
Surprise--------------------------------------
TimingPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hours--Pre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hours----------------------

Key Statistics & Ratios

Market Cap199.24B
Enterprise Value157.67B
Trailing P/E0.00
Forward P/E0.00
Price / Sales9.68
Price / Book3.19
Revenue (TTM)20.59B
Gross Profit (TTM)5.65B
EBITDA-4.77B
Profit Margin-54.13%
Operating Margin-75.35%
Return on Equity-18.98%
Return on Assets-8.39%
Shares Outstanding28.10M
Shares Float23.12M
Beta0.64
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Sep 17, 20266:5
  • Jul 15, 20263767:3644
  • Oct 24, 202213:10
  • Sep 2, 20221623:1544
  • Aug 4, 20206:5
  • Jun 23, 20201811:1586